Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.

Human molecular genetics - 1 Sept 1995

Williamson M P, Elder P A, Shaw M E, Devlin J, Knowles M A

Abstract excerpt

The p16 gene has been identified as a candidate tumour suppressor gene at 9p21, a region commonly deleted in bladder cancer. We screened 140 bladder tumours and 16 cell lines for deletions and sequence variants of p16. Eight cell lines showed homozygous deletion of p16 and two had small sequence...

Topics

Base Sequence
Carrier Proteins
Chromosome Mapping
Chromosomes, Human, Pair 9
Cyclin-Dependent Kinase Inhibitor p16
DNA Primers
Gene Deletion
Genes, Tumor Suppressor
Homozygote
Humans
Molecular Sequence Data
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Polymorphism, Single-Stranded Conformational

Tumor Cells, Cultured

Urinary Bladder Neoplasms

Source

Identifiers

PMID: 8541841
DOI: 10.1093/hmg/4.9.1569

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-8541841-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.PMID 8541841Read ↗

Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.Semantic proximity Read ↗

Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction.Semantic proximity Read ↗

Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas.Semantic proximity Read ↗

Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.Semantic proximity Read ↗

Deletion of the p16 and p15 Genes in Human Bladder TumorsSemantic proximity Read ↗

Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer.Semantic proximity Read ↗

Role of chromosome 9 in human bladder cancer.Semantic proximity Read ↗

Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.Semantic proximity Read ↗

Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.Semantic proximity Read ↗

Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer.Semantic proximity Read ↗

Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.Semantic proximity Read ↗

Evidence for two candidate tumour suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumour cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.